A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder
Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obsessive-Compulsive Disorder
Intervention: behavior therapy (Behavioral); D-Cycloserine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Massachusetts General Hospital Official(s) and/or principal investigator(s): Sabine Wilhelm, PhD, Principal Investigator, Affiliation: Massachusetts General Hospital David Tolin, PhD, Principal Investigator, Affiliation: Hartford Institute of Living
Summary
This study examines the efficacy of the medication D-Cycloserine in the reduction of
obsessions and compulsions in individuals with obsessive-compulsive disorder (OCD). All
study participants will receive Exposure and Response Prevention, a common form of behavior
therapy for individuals with OCD. Half (50%) of the participants will be randomly assigned
to the placebo condition and the other half (50%) will be randomly assigned to receive
D-Cycloserine. Because all participants will receive 10 sessions of behavior therapy, all
participants are expected to improve from this treatment.
Clinical Details
Official title: A Randomized, Double-blind, Placebo-controlled Medication Trial With D-Cycloserine for Individuals With Obsessive-compulsive Disorder Currently Receiving Behavior Therapy
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: significant reduction of OCD symptoms after the completion of treatment
Secondary outcome: significant reduction of depressive symptoms after the completion of treatment
Detailed description:
The study consists of Behavior Therapy (Exposure and Response Prevention; ERP) for OCD.
Specifically, it involves exposure to anxiety-provoking situations and response-prevention
of any rituals. ERP has shown to be effective for many individuals with OCD.
All assessments and treatment sessions are at no cost to the patients. 50% of the patients
will randomly be assigned to the D-Cycloserine (DCS) condition, and 50% of the patients will
be assigned to a placebo condition. D-Cycloserine is FDA-approved for the treatment of
Tuberculosis. However, recent research in other anxiety disorders has shown that
D-Cycloserine plus Behavior Therapy is more effective than Behavior Therapy alone.
This treatment study has two active conditions. That is, all patients will receive Behavior
Therapy and we do expect that everybody will improve from this treatment. However, it may be
that those patients in the DCS condition will improve somewhat more than those in the
placebo condition.
The treatment will be structured with homework and repeated assessments every 4 weeks.
Assessments are extremely important as they guide the treatment and provide the study
investigators necessary information about the treatment. The treatment consists of 10
sessions (twice a week) plus post-treatment and follow-up assessments at 1 and 6 months.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Meets diagnosis for obsessive-compulsive disorder
Exclusion Criteria:
- History of psychotic disorders
- History of neurological disorders
- History of bipolar disorders
Locations and Contacts
Anxiety Disorders Center, The Institute of Living, Hartford, Connecticut 06106, United States
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information
This link will connect you to the main website of the Anxiety Disorders Center at the Institute of Living in Hartford, CT
Starting date: December 2003
Last updated: July 27, 2009
|